Therapeutic HIV Vaccine Trials at Vaccine Research Center at NIH

[Guest guest]

Study to Assess Effectiveness of a Vaccine Utilizing Boost Based on

GenVec's Adenovector Technology and Proprietary Cell Line to Treat

Patients Infected with Most Common Strains of HIV

GenVec Vaccine Technology Enters First HIV Human Therapeutic

Clinical Trials at Vaccine Research Center at NIH

GAITHERSBURG, Md.--(BUSINESS WIRE)--Aug. 22, 2006

GenVec, Inc. (Nasdaq:GNVC) announced today that the first human

therapeutic clinical trial involving the company's adenoviral-vector

technology used in an HIV vaccine candidate will be conducted by the

Vaccine Research Center (VRC), National Institute of Allergy and

Infectious Diseases, National Institutes of Health (NIH) in

Bethesda, MD.

These will be the first human trials to assess the effectiveness of

a " prime-boost " vaccine using GenVec's adenovector technology as a

potential therapy for patients infected with HIV. The randomized,

placebo-controlled study will measure safety and immunogenicity, in

15 HIV positive patients.

The trial will combine two components, a DNA prime vaccine and

GenVec's adenovector-based technology used in the boost vaccine. The

adenovector-based boost vaccine was developed using the company's

proprietary technology and 293-ORF6 cell line.

Patients in the study will be treated with the first vaccine (known

as DNA prime) followed by a booster with the second vaccine (known

as rAD5 boost), and will be evaluated for 48 weeks. The clinical

trial will be conducted by the VRC as part of a broad effort to test

HIV vaccines based on GenVec's adenovector delivery technology and

cell line.

" We continue to see great promise for our proprietary adenovector

delivery technology for the development of an effective HIV vaccine.

In preclinical and clinical studies, our vaccine candidates have

demonstrated a broad antibody and T-cell responses against HIV,

clades A, B and C.

We look forward to the completion of human studies to assess the

effectiveness of these products as therapeutic options for

patients, " said Dr. Rick King, GenVec's senior vice president of

research.

In October 2005, the VRC announced the initiation of Phase II

testing of a prime/boost preventative vaccine utilizing GenVec's

adenovector technology. In addition, seven Phase I trials of the

preventative vaccine have completed enrollment and more than 600

healthy participants have received the adenovector vaccine candidate

boost to date.

The rate of new HIV infections has continued to increase,

particularly in developing countries. The Joint United Nations

Programme on HIV/AIDS and the World Health Organization estimate

that as many as 6.4 million new cases of HIV/AIDS were diagnosed and

roughly 40 million people worldwide were living with HIV/AIDS at the

end of 2004. As many as 30 million people worldwide have died as a

result of HIV infection since the epidemic began.

GenVec, Inc. is a biopharmaceutical company developing novel gene-

based therapeutic drugs and vaccines. GenVec has several adenovector

(DNA carrier)-based vaccines currently in development against a

variety of diseases, including HIV, malaria, pandemic flu and foot

and mouth disease.

Additional information on GenVec and its portfolio of product

candidates is available at www.genvec.com and in the company's

various filings with the Securities and Exchange Commission.

Contacts

GenVec, Inc.

W. Church, 240-632-5510

jchurch@...